Quratis (KOSDAQ:A348080) - Stock Price, News & Analysis

A348080 Stock Overview

Engages in developing vaccines in South Korea. More details

A348080 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Highly volatile share price over the past 3 months compared to the KR market

Does not have a meaningful market cap (₩33B)

Shareholders have been diluted in the past year

Quratis Inc. Competitors

Aptamer Sciences

KOSDAQ:A291650

₩33.1b

Daesung Microbiological Labs

KOSDAQ:A036480

₩35.9b

Cell Bio Human TechLtd

KOSDAQ:A318160

₩30.3b

GeneBioTech Ltd

KOSDAQ:A086060

₩29.6b

Price History & Performance

Summary of all time highs, changes and price drops for Quratis
Historical stock prices
Current Share Price	₩698.00
52 Week High	₩2,870.00
52 Week Low	₩622.00
Beta	0
11 Month Change	-14.67%
3 Month Change	-0.57%
1 Year Change	-73.15%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-88.07%

Recent updates

Shareholder Returns

	A348080	KR Biotechs	KR Market
7D	-3.2%	-8.1%	2.9%
1Y	-73.2%	18.1%	-2.8%

Return vs Industry: A348080 underperformed the KR Biotechs industry which returned 18.1% over the past year.

Return vs Market: A348080 underperformed the KR Market which returned -2.8% over the past year.

Price Volatility

Is A348080's price volatile compared to industry and market?
A348080 volatility
A348080 Average Weekly Movement	12.7%
Biotechs Industry Average Movement	8.1%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	11.6%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A348080's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A348080's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2016	n/a	n/a	www.quratis.com

Quratis Inc. engages in developing vaccines in South Korea. It is involved in developing QTP101, a vaccine for tuberculosis; dendritic cell-based cell therapy for indications, including cancer, autoimmune, and infectious diseases; and peptide nucleic acid-based antimicrobial agents. The company also offers drugs contract development and manufacturing services.

Quratis Inc. Fundamentals Summary

How do Quratis's earnings and revenue compare to its market cap?
A348080 fundamental statistics
Market cap	₩32.91b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A348080 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A348080 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A348080 perform over the long term?

See historical performance and comparison

Quratis KOSDAQ:A348080 Stock Report